Gate2Brain technology will enable the development of new therapies for the central nervous system
The publication of two articles in the scientific journal Molecular Pharmaceutics validates the innovative approach of the University of Barcelona spin-off, Gate2Brain, to cross the blood-brain barrier and opens a new stage for its technology: beyond pediatric brain tumors, the shuttle peptides developed by the company demonstrate that they can transport a wide variety of drugs to the brain.
This advance is particularly relevant in the field of therapies directed at the central nervous system, where many drugs have difficulty reaching their target due to the brain’s natural protection. The published studies demonstrate that Gate2Brain’s technological platform can overcome this barrier, opening the door to new clinical applications.
Scientific validation in two key directions:
– Antibodies that reach the brain and combat metastasis. One of the studies has shown that combining a Gate2Brain peptide with the antibody trastuzumab improves its ability to reach the brain and significantly reduces brain metastases in preclinical models. This innovative combination opens up new therapeutic possibilities for the treatment of brain tumors and other neurological diseases.
– A versatile tool for many types of drugs. The other article reviews advances in transporter peptides and highlights how Gate2Brain’s technology can facilitate the entry of multiple types of drugs into the brain: from small molecules to proteins and nanoparticles.
These results consolidate the proposal of Gate2Brain as a promising tool to improve the treatment of diseases such as Alzheimer’s, glioblastoma or other neurodegenerative disorders.
Gate2Brain is a biotechnology company created in 2020 and focused on the development of therapies that efficiently cross biological barriers such as the blood-brain barrier, thus facilitating the arrival of drugs to the brain. The company is also a spin-off of the Institute for Research in Biomedicine of Barcelona (IRB Barcelona), and the Sant Joan de Déu Research Institute of the Hospital Sant Joan de Déu (SJD). In 2023 it was recognized with the Senén Vilaró Award from the UB Social Council and the Bosch i Gimpera Foundation for the best innovative company of the year.